EN001 ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
10Charcot-Marie-Tooth disease1
113Muscular dystrophy1

10. Charcot-Marie-Tooth disease


Clinical trials : 41 Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05333406
(ClinicalTrials.gov)
February 22, 20226/1/2022Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1AOpen-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1ACharcot-Marie-Tooth Disease, Type IADrug: EN001ENCellNULLCompleted19 Years75 YearsAll9Phase 1Korea, Republic of

113. Muscular dystrophy


Clinical trials : 646 Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05338099
(ClinicalTrials.gov)
January 18, 20226/1/2022Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)Duchenne Muscular DystrophyDrug: EN001ENCellNULLCompleted2 Years18 YearsMale7Phase 1Korea, Republic of